In many emerging biotech companies, CRO selection is treated as a procurement exercise. Proposals are collected, costs are compared, and the lowest credible bid wins. That approach misses the point. Choosing a CRO or major clinical vendor is one of the most consequential decisions a sponsor will make, and it deserves executive ownership.
The reason is simple. Your CRO will shape your timeline, your data quality, your relationships with investigators, and ultimately your regulatory submission. A price advantage in the proposal can disappear quickly through change orders, turnover, and missed milestones.
Executive leaders bring a different lens to vendor selection. They start by defining what the program actually needs. Is therapeutic area depth more important than global reach? Does the study require specialized patient recruitment, complex biomarker logistics, or a rare disease network? Clear requirements lead to a sharper request for proposal and more comparable responses.
Leaders also look beyond the sales presentation. Who will actually work on the study? What is their experience, and how much of their time is committed? How does the CRO handle scope changes, and what does their change order history look like with similar sponsors? Reference calls should be pointed and specific.
Fit matters as much as capability. A large CRO may offer scale but treat a small sponsor as a low priority. A mid-sized or specialty CRO may provide more attention but less infrastructure. The right choice depends on the program, the sponsor's internal capacity, and the kind of partnership the company wants.
Finally, executive ownership continues into contracting. The contract should reflect the promises made during bid defense, with clear assumptions, milestones, and performance expectations. Gaps between the proposal and the contract are where many sponsor-CRO relationships begin to fail.
ABRA Clinical Consulting has deep experience on both sides of the table, having led operations inside global CROs. We help sponsors run fit-for-purpose vendor selection processes that lead to stronger partnerships and fewer surprises.
